Staff and Wire Reports
Tuesday, 30 June 2009 19:15
June 30 (Reuters) - Sequenom, Inc. (NASDAQ:SQNM) said the U.S. Securities and Exchange Commission has initiated an investigation related to the company's Down Syndrome test SEQureDx, sending its shares down 8 percent.
In April, the San Diego-based company had delayed launch of the test, citing mishandling of research and development test data and results by an employee.
Sequenom said the company intends to cooperate completely with the regulator's investigation and the company's internal investigation was ongoing.
Shares of Sequenom were down 8 percent at $3.60 after the bell. They closed at $3.91 Tuesday on Nasdaq. (Reporting by Vidya L Nathan in Bangalore; Editing by Vinu Pilakkott)
Sequenom's Speculative Shares Lift Off on Tuesday
Sequenom Splattered, EXACT Sciences on the Rise
Sequenom Affirms Offer for EXACT Sciences
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.
Add this page to your favorite Social Bookmarking websites